Funding opportunity for modelling HPV, Hep B, pneumococcal disease, rotavirus and Hib
The Vaccine Impact Modelling Consortium (www.vaccineimpact.org) was launched in 2016 for a five-year period in response to an identified need by Gavi and the Bill & Melinda Gates Foundation to estimate global vaccine impact more consistently and reliably. The funders use the results to track progress, to project the likely future impact of vaccines in the current portfolio as well as to forecast the impact of potential future investments.
The Consortium coordinates the ongoing work of modelling groups from a range of research institutions and is led by a secretariat based at Imperial College London. We are looking for modelling groups interested in joining the Consortium and able to meet the output requirements as stipulated by the secretariat and the funders. The current portfolio of diseases includes: hepatitis B, Hib (Haemophilus influenzae type b), human papilloma virus (HPV), Japanese encephalitis, measles, meningitis A, pneumococcus, rubella, rotavirus, and yellow fever.
Through this open call, we are looking to recruit models for HPV, Hepatitis B, pneumococcal disease, rotavirus and Hib. At a maximum, the Consortium can fund two modelling groups per disease area. Current Consortium models in the specified disease areas will be requested to re-apply along with the external groups.
Timeline:
Closing date: 13 June 2018
Review outcomes: August 2018
Duration: 12 months in the first instance (with a strong possibility of renewal for the duration of the Consortium)
Funds available: up to $65,000
For more information about how to apply, please visit https://www.vaccineimpact.org/2018-05-02-request-for-proposals/
- Type
- Other
- Institution
- Any
- City
- Any
- Country
- Any
- Closing date
- June 13th, 2018
- Posted on
- May 4th, 2018 10:11
- Last updated
- May 4th, 2018 10:11
- Share
- Tweet